Status:
COMPLETED
Effect of Single Dose Intranasal Insulin On Cognitive Function
Lead Sponsor:
University of Massachusetts, Worcester
Conditions:
Schizophrenia
Schizoaffective Disorder
Eligibility:
All Genders
18-65 years
Phase:
PHASE4
Brief Summary
The purpose of the study is to find out how a small dose of insulin might affect memory, the ability to concentrate, and improve your daily functioning in patients with schizophrenia and schizoaffecti...
Detailed Description
Insulin signaling in the brain is associated with improved cognitive function in both animal and human studies. Intranasal administration of insulin, which is non-invasive and minimizes the risk of hy...
Eligibility Criteria
Inclusion
- Age 18-65 years
- Diagnosis of schizophrenia, any subtype or schizoaffective disorder, any subtype
- Male or female
- Stable dose of the current antipsychotic drug for at least one month
- Well established compliance with out-patient treatment per treating clinician's judgement.
- Able to complete the cognitive assessment battery (must be English speaking)
Exclusion
- Inability to provide informed consent
- Current substance abuse
- On clozapine or olanzapine
- Psychiatrically unstable per treating clinician's judgement.
- Significant medical illnesses including uncontrolled hypertension, diabetes, seizure disorder, severe cardiovascular, cerebrovascular, pulmonary, or thyroid diseases etc.
- Incapable to complete the cognitive battery assessment.
Key Trial Info
Start Date :
October 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2010
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT00646581
Start Date
October 1 2006
End Date
January 1 2010
Last Update
February 15 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Freedom Trail Clinic
Boston, Massachusetts, United States, 02114